Unknown

Dataset Information

0

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

ABSTRACT:

SUBMITTER: Naing A 

PROVIDER: S-EPMC8436252 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
| S-EPMC7255545 | biostudies-literature
Unknown A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
| S-EPMC4294348 | biostudies-literature
Unknown Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
| S-EPMC7186583 | biostudies-literature
Unknown Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study.
| S-EPMC8655428 | biostudies-literature
Unknown Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.
| S-EPMC7709506 | biostudies-literature
Unknown Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
| S-EPMC5991615 | biostudies-literature
Unknown An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.
| S-EPMC7406114 | biostudies-literature
Unknown Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
| S-EPMC3954701 | biostudies-literature
Unknown Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
| S-EPMC6386027 | biostudies-literature
Unknown Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
| S-EPMC5476941 | biostudies-literature